Scholar Rock Holding (SRRK) Capital Expenditures (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Capital Expenditures of $37000.0 for Q1 2026, down 86.35% year-over-year from $271000.0 in Q1 2025, and up 15.62% quarter-over-quarter from $32000.0 in Q4 2025.
Powered by 
Analysis
Scholar Rock Holding (SRRK) Capital Expenditures (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Capital Expenditures history runs 10 years deep, the most recent figure standing at $37000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 86.35% year-over-year to $37000.0; the TTM figure through Mar 2026 stood at $368000.0 (down 46.2% YoY), while the FY2025 annual figure was $602000.0, up 514.29% from the prior year.
- Capital Expenditures for Q1 2026 stood at $37000.0, up from $32000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $3.1 million in Q4 2023, with the low at -$653000.0 in Q3 2024.
- The 5-year median for Capital Expenditures is $37000.0 (2026), against an average of $264647.1.
- Peak annual rise in Capital Expenditures reached 344.9% in 2024, while the deepest fall reached 1150.0% in 2024.
- Scholar Rock Holding's Capital Expenditures stood at $952000.0 in 2022, then soared by 224.05% to $3.1 million in 2023, then slumped by 77.12% to $706000.0 in 2024, then tumbled by 95.47% to $32000.0 in 2025, then climbed by 15.62% to $37000.0 in 2026.
- Business Quant data shows SRRK's Capital Expenditures at $37000.0 in Q1 2026, $32000.0 in Q4 2025, and $551000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Scholar Rock Holding | 7.25 Bn | 7.25 Bn | - | -1.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.85 Mn |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 32,000.00 |
| Sep 30, 2025 | 84,000.00 |
| Jun 30, 2025 | 215,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Dec 31, 2024 | -864,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | -305,000.00 |
| Mar 31, 2024 | -315,000.00 |
| Dec 31, 2023 | 3.09 Mn |
| Sep 30, 2023 | -270,000.00 |
| Jun 30, 2023 | -51,000.00 |
| Mar 31, 2023 | -66,000.00 |
| Dec 31, 2022 | 117,000.00 |
| Sep 30, 2022 | 27,000.00 |
| Jun 30, 2022 | 477,000.00 |
| Mar 31, 2022 | 443,000.00 |
| Dec 31, 2021 | 542,000.00 |
| Sep 30, 2021 | 1.41 Mn |